Vistagen therapeutics stock.

Find the latest SEC Filings data for VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.

Vistagen therapeutics stock. Things To Know About Vistagen therapeutics stock.

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing ...See Vistagen Therapeutics, Inc. (VTGN) history of stock splits. Includes date and ratio.According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00.Oct 28, 2022 · SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 6, 2023-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common ...

Mental Health America’s prestigious national certification complements Vistagen’s ongoing efforts to improve mental health care across the U.S. Timely recognition comes during Mental Health...VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.

Dec 1, 2023 · Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly Results; Section 16 Filings; Corporate Governance Executive Team; Board Committees; Documents & Charters William Blair initiated coverage on VistaGen Therapeutics Inc VTGN, a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other mental health conditions.. The lead product Fasedienol (PH94B), is an intranasal pherine and is in late-stage development …

Medical, dental and vision premiums are paid at 100% for employees. Competitive wages. Unlimited paid time off (PTO) Paid holidays. Flexible work locations. Employee stock purchase plan. Follow us on LinkedIn. Apply to join Vistagen today. If you are interested in joining the Vistagen team, but do not see a job that matches your skill set ...VistaGen Therapeutics has raised a total of. $154.8M. in funding over 8 rounds. Their latest funding was raised on Oct 2, 2023 from a Post-IPO Equity round. VistaGen Therapeutics is registered under the ticker NASDAQ:VTGN . VistaGen Therapeutics is funded by 9 investors. BVF Partners and TCG Crossover are the most recent investors.Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Fuji Pharma Co., Ltd. (“Fuji”) (TSE: 4554), a pharmaceutical company specializing in development, manufacture and …Vistagen to conduct small U.S. Phase 1 trial with newly optimized formulation of PH10 in Q1 2023 to confirm favorable safety profile from three previous clinical trials and to facilitate Phase 2B development of PH10 for major depressive disorder. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 30, 2022-- Vistagen, (NASDAQ: …Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.

Nov 6, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...

The VistaGen Therapeutics Inc stock price gained 7.16% on the last trading day (Friday, 24th Nov 2023), rising from $3.35 to $3.59. During the last trading day the stock fluctuated 8.30% from a day low at $3.37 to a day high of $3.65. The price has risen in 8 of the last 10 days and is up by 24.22% over the past 2 weeks.

Cerevel's stock doubled to $25.20 a share after the company put out the data in a press release. ... recently initiated coverage of VistaGen Therapeutics and pegged the company as a hidden gem.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ...At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small ...Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety ...Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022. …

Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly Results; …VistaGen Therapeutics Inc stock performance at a glance. Check VistaGen Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ...As of August 10, 2023, the Company had 9,362,444 shares of common stock outstanding. Conference Call. Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update. U.S. Dial-in ... VISTAGEN THERAPEUTICS, INC.William Blair initiated coverage on VistaGen Therapeutics Inc VTGN, a clinical-stage biopharmaceutical company focused on developing next-generation …There are 137 funds or institutions reporting positions in VistaGen Therapeutics. This is a decrease of 34 owner (s) or 19.88% in the last quarter. Average portfolio weight of all funds dedicated ...

The recent price decline of 15% in VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) stock may have disappointed insiders who bought US$190k worth of shares at an average price of US$0.17 in the past 12 ...According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI is also known a narrow therapeutic index or critical dose d...

Benzinga - by Vandana Singh, Benzinga Editor. William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other mental health conditions.. The lead product …2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ... William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ...Get the latest Viking Therapeutics Inc (VKTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.VistaGen Therapeutics Inc (NASDAQ:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) …According to data from Benzinga Pro, VistaGen Therapeutics shares were up 17.6%, trading at $0.16 at the time of publication. The stock has a 52-week high of $1.79 and a 52-week low of $0.08.Medical, dental and vision premiums are paid at 100% for employees. Competitive wages. Unlimited paid time off (PTO) Paid holidays. Flexible work locations. Employee stock purchase plan. Follow us on LinkedIn. Apply to join Vistagen today. If you are interested in joining the Vistagen team, but do not see a job that matches your skill set ...

Vistagen (NASDAQ:VTGN) to implement a stockholder-approved a one-for-thirty reverse stock split of its outstanding shares of common stock, effective June 7, 2023.The primary corporate and ...

Jun 30, 2021 · Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ...

VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Get a real-time VistaGen Therapeutics, Inc. (VTGN) stock price quote with breaking news, financials, statistics, charts and more.On average, Wall Street analysts predict. that Vistagen Therapeutics's share price could reach $21.00 by Nov 14, 2024. The average Vistagen Therapeutics stock price prediction forecasts a potential upside of 484.96% from the current VTGN share price of $3.59.Jul 18, 2023 · Vistagen Therapeutics. VTGN. $2.57-0.32 (-11.07%) Share Price. as of November 10 4:00:00 PM EST. Vistagen Therapeutics (VTGN) Stock Price Performance. More on Forbes. ... therapies and ... Get Vistagen Therapeutics Inc (VTGN.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.Maxim Group analyst Jason McCarthy maintained a Buy rating on VistaGen Therapeutics (VTGN – Research Report) yesterday and set a price target of $30.00.The company’s shares closed today at $6. ...Mar 9, 2023 · Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $179.6 thousand and a GAAP net loss of $9.76 million. VistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss SA News Fri, Aug. 12, 2022 2 Comments VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M ...VistaGen Therapeutics Inc chart This market's chart. This is a visual representation of the price action in the market, over a certain period of time. You can use this to help gauge a …MT. Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating. Oct. 17. MT. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8.

If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the last participant has completed the study protocol in its U.S. Phase 1 clinical trial of itruvone (PH10), the …Mar 22, 2023 · VistaGen Therapeutics ( NASDAQ: VTGN) jumped ~17% on Wednesday morning after announcing data from a Phase 3 trial for its experimental nasal spray for social anxiety disorder (SAD), fasedienol ... Instagram:https://instagram. yyy stock pricebest dental insurance in fltmobile dividendsford motor ex dividend date VistaGen Therapeutics Inc stock performance at a glance. Check VistaGen Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Find the latest Vistagen Therapeutics, Inc. (VTGN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. value of silver dollar 1921corebridge annuities The average price target represents a 123.64% change from the last price of $3.13.Based on 4 Wall Street analysts offering 12-month price targets for VistaGen Therapeutics in the last 3 months, the average price target is $7.00 with a high forecast of $9.00 and a low forecast of $5.00. buy stocks with crypto Learn more about whether Vistagen Therapeutics Inc is a good stock to buy or sell based on recent news as well as its key financial metrics. Read on to find out how grades on certain investment factors and determine whether it meets your investment needs. Latest Vistagen Therapeutics Inc Stock NewsGet the latest Vistagen Therapeutics Inc (VTGN) stock quote, charts, news, and other financial information to help you make more informed trading and investment …Vistagen is requesting approval from its stockholders to have the option to implement a Reverse Split if it becomes necessary to increase the per share price and bid price of the Company’s common stock in order to regain compliance with the $1.00 minimum bid price requirement of Nasdaq and maintain its Nasdaq listing.